Luke Carlson, MD
Vascular & Interventional Radiology · Dallas, TXNPI 1972704807
Payments from drug & device makers
Across 51 payments — averaging $71.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Terumo Medical Corporation$1K
- Inari Medical, Inc.$194
- Philips North America LLC$154
- Tactile Systems Technology Inc$123
- Cardiva Medical, Inc.$112
- plus $324 from 10 others
What the payments were for
- Travel & lodging$1,92353%
- Food & beverage$1,69847%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 18 | $1,479 |
| Terumo Medical Corporation | 9 | $1,236 |
| Inari Medical, Inc. | 2 | $194 |
| Philips North America LLC | 2 | $154 |
| Tactile Systems Technology Inc | 3 | $123 |
| Cardiva Medical, Inc. | 2 | $112 |
| Boston Scientific | 4 | $68 |
| Nevro Corp. | 3 | $64 |
| Angiodynamics, Inc. | 1 | $56 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $23 |
| Shield Therapeutics Inc | 1 | $22 |
| Merit Medical Systems Inc | 1 | $21 |
| Globus Medical | 1 | $16 |
| Bard Peripheral Vascular, Inc. | 1 | $15 |
| Cashflow Solutions, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLIDESHEATH SLENDER$1,152
- VenaSeal$938
- FLOWTRIEVER CATHETER, S$216
- Turbo Power$124
How this compares
$3,622 in reported general payments places this provider in the 50th percentile of 299 vascular & interventional radiology providers in Texas.
See all vascular & interventional radiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 19 | $11,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $23 | $11,09419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 299 vascular & interventional radiology providers in Texas.
Other vascular & interventional radiology in Dallas
- Sanjeeva KalvaDallas$581K
- Patrick SutphinDallas$346K
- Aaron FrittsDallas$101K
- Dev BatraDallas$72K
- Stephen HumphreyDallas$63K
- Samuel RiceDallas$61K
- Roberta NovakovicDallas$44K
- Travis van MeterDallas$40K
- Steve HongDallas$28K
- Seung KimDallas$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.